Device Trial Radar · NCT05026281
Bleeding Oral Anticoagulant Analyzer (BOA)
Last checked: Nov 20, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Dec 16, 2021
Primary completion
Jan 31, 2024
Study completion Jan 31, 2024
Sponsor
- Lead sponsor
- University Hospital, Clermont-FerrandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hôpital Edouard Herriot; University Hospital of Saint-Etienne; University Hospital, Grenoble; University Hospital, Tours; Pitié-Salpêtrière Hospital
- First posted
- Aug 30, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The quality of the reversion of these serious hemorrhagic accidents under oral anticoagulants depends on the adequate use of reversion products but also on the speed of obtaining hemostasis data allowing to evaluate the effectiveness of this "chemical" hemostasis. . Clot formation can be studied using different visco-elastic methodologies (thromboelastography or thromboelastometry) with a detectable change in clot formation with oral anticoagulants. These techniques have been proven in patients who are often unstable and present with severe trauma with hemorrhagic shock, thus making it possible to guide the transfusion protocol. However, the level of recommendations in these patients, who are often polyhydrated and poly-transfused, is grade 1c due to small-scale studies with difficulty in analyzing the values of the visco-elasticity parameters in these patients. In addition, these methods are little used in current practice because of their difficult reading. The use of visco-elastic methods in patients on oral anticoagulants has been little studied. However, taking an oral anticoagulant mainly causes coagulation disorders. The use of these methods would make it possible to assess the impact of the anticoagulant on hemostasis and to verify the correct reversion of hemostasis parameters. Quantra®, one of the visco-elastic methods, would make it possible to speed up the evaluation in the context of biology relocated to the patient's bed with a simplified reading of the factors involved in the formation of the clot in order to allow an immediate evaluation the quality of the reversion performed which may have an impact on the re-administration of reversion products or even an adaptation of the dose of reversion products according to the initial parameters at the time of severe bleeding before reversion. The objective of this pilot study is to study the metrological evolution, before and after reversion, of the hemostasis parameters evaluated by the Quantra® system from HemoSonics in a patient being his own control in the context of a severe hemorrhage occurring on oral anticoagulants (VKA or DOA).
Conditions
- Anticoagulants and Bleeding Disorders
Interventions
Quantra analyzerDevice
one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in viscoelastic hemostasis parameters assessed by the Quantra® system in the context of severe bleeding occurring under oral anticoagulants (VKA or DOA)Time frame: Hour 0 and Hour 0+30min
- Change in viscoelastic hemostasis parameters assessed by the Quantra® system in the context of severe bleeding occurring under oral anticoagulants (VKA or DOA)Time frame: Hour 0 and Hour 0+30min
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University Hospital
Clermont-Ferrand, France
Grenoble University Hospital
Grenoble, France
Edouard Herriot University Hospital
Lyon, France
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.